Sequencing of MET Inhibitors in Lung Cancer: Have We Met the Target?

Affiliations

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
² Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: limlove2008@yuhs.ac.

Free article

Editorial

Chang Gon Kim et al. J Thorac Oncol. 2021 May.

Free article

. 2021 May;16(5):709-711.

doi: 10.1016/j.jtho.2021.02.017.

¹ Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea.
² Division of Medical Oncology, Department of Internal Medicine, Yonsei Cancer Center, Yonsei University College of Medicine, Seoul, South Korea. Electronic address: limlove2008@yuhs.ac.

No abstract available

Comment on

A Phase 2 Study of Capmatinib in Patients With MET-Altered Lung Cancer Previously Treated With a MET Inhibitor.
Dagogo-Jack I, Moonsamy P, Gainor JF, Lennerz JK, Piotrowska Z, Lin JJ, Lennes IT, Sequist LV, Shaw AT, Goodwin K, Stevens SE, Do A, Digumarthy SR, Price K, Muzikansky A, Hata AN, Heist RS. Dagogo-Jack I, et al. J Thorac Oncol. 2021 May;16(5):850-859. doi: 10.1016/j.jtho.2021.01.1605. Epub 2021 Feb 3. J Thorac Oncol. 2021. PMID: 33545388 Free PMC article. Clinical Trial.